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Abstract
Background: The two core neuroacanthocytosis (NA) syndromes, chorea-acanthocytosis (ChAc) and McLeod syndrome, are progressive neurodegenerative
disorders that primarily affect the basal ganglia. The characteristic phenotype comprises a variety of movement disorders including chorea, dystonia, and
parkinsonism, as well as psychiatric and cognitive symptoms attributable to basal ganglia dysfunction. These disorders are symptomatically managed on a case-by-
case basis, with very few practitioners seeing more than a single case in their careers.
Methods: A literature search was performed on PubMed utilizing the terms neuroacanthocytosis, chorea-acanthocytosis, and McLeod syndrome, and articles were
reviewed for mentions of therapies, successful or otherwise.
Results: There have been no blinded, controlled trials and only one retrospective case series describing ChAc. The various therapies that have been used in
patients with NA syndromes are summarized.
Discussion: Management remains at present purely symptomatic, which is similar in principle to other more common basal ganglia neurodegenerative disorders
such as Huntington’s disease (HD) and Parkinson’s disease (PD). However, there are some specific issues particular to NA syndromes that merit attention. An
integrated multidisciplinary approach is the ideal management strategy for these complex and multifaceted neurodegenerative disorders.
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Introduction
The two core neuroacanthocytosis (NA) syndromes are chorea-
acanthocytosis (ChAc), which is autosomal recessive, and McLeod
syndrome, which is inherited in an X-linked manner. These disorders
share a number of similar features including chorea, dystonia,
peripheral neuropathy, myopathy, seizures, and psychiatric symptoms,
and there can be a striking phenotypic overlap.1–3
Due to the rarity of these conditions, all reports of therapies are
anecdotal, and no controlled clinical trials have been performed. The
only significant case series that has been published is a retrospective
survey of 15 patients with ChAc who underwent deep brain stimulation
(DBS) at 11 centers internationally,4 which constitutes level 4 evidence.
Treatment for most of the symptoms of NA syndromes is based
upon empiric evidence from patients with other conditions. For
example, the effects of botulinum toxin injections for dystonia have
been systematically studied in a controlled, blinded manner primarily
in patients with isolated cervical dystonia and occasionally with
isolated dystonia affecting other regions. More complex dystonia such
as that involving the lower facial area and tongue is challenging to
study in a systematic manner due to the variability of affected muscle
groups. In McLeod syndrome, it is possible to anticipate and prepare
for cardiac and hematological complications.
The ideal approach to these complex neurodegenerative disorders,
as in Parkinson’s disease (PD),5,6 is a multi-disciplinary, holistic
approach employing physical, occupational, and speech therapists, in
addition to nurses, social workers, and neurologists with expertise in
movement disorders.7 While the availability of particular therapies
may be limited, especially when there is no clear potential for
improvement, it is essential to recognize that functions can be
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maintained with appropriate, ongoing activities. In the face of apparently
relentless disease progression and ongoing deterioration of motor and
cognitive functions, it can be helpful to identify specific and realistic
goals. For example, it is beneficial to coordinate injections of
botulinum toxin for focal dystonia with therapies aimed at
maximizing specific functions such as speech and swallowing.7
In an attempt to synthesize the current available knowledge, here I
review the data, primarily in the form of single case reports, small
series, and personal and anecdotal evidence, for the management of
ChAc and McLeod syndrome. In addition, I discuss the issue of
performing clinical trials in very rare disorders, and the role of online
patient-oriented resources for patients, caregivers, and clinicians.
Methods
A literature search was performed on PubMed utilizing the terms
neuroacanthocytosis (n5191, excluding review articles), chorea-
acanthocytosis (n5314, excluding review articles), and McLeod
syndrome (n5124, excluding review articles). All articles in English
were reviewed for their mention of therapies, successful or otherwise.
All reports were from university clinics, as far as could be ascertained.
The majority of reports were of single cases, except as noted. Where




Orolingual dystonia. ChAc can present with a wide spectrum of
symptoms that may vary over time. When present, a characteristic
movement disorder of ChAc is dystonia involving the lower face and
tongue,8 precipitated specifically by eating. While a similar phenom-
enon may be occasionally seen in other disorders including tardive
dyskinesia, McLeod syndrome, and pantothenate kinase-associated
neurodegeneration (PKAN),9 the severity of this symptom, dispropor-
tionate to other involuntary movements, strongly suggests ChAc. In
addition, the self-mutilating tongue and lip biting that are often
present10 are not yet reported in the other conditions. These
movements can be very painful and damaging, in addition to
interfering with feeding and speech and being socially embarrassing.
Management of this symptom can be very challenging. Some
patients have all of their teeth removed to reduce cheek, lip, and
tongue biting. Others use a mechanical device such as a stick to reduce
biting and tooth-grinding. These objects may also reduce dystonia by
functioning as a sensory trick. Bite guards can be helpful but are often
expensive, wear out, and interfere with eating. Some patients will use
an absorbent item like a towel, which also absorbs saliva.
Botulinum toxin injected into the genioglossus may reduce tongue
protrusion (two patients, dose not available: one patient—125 units of
abobotulinum toxin into the genioglossus).7,9 Alternatively, 10 units of
onabotulinum toxin to each muscle under ultrasound guidance can be
successful in improving eating and speech.11 As this muscle protrudes the
tongue, weakening it should not theoretically result in airway obstruc-
tion; however, most physicians are cautious about such injections,
especially with the potential of spread to other muscles involved in
swallowing. Electromyogram-targeted injections of 35 units of onabo-
tulinum toxin into the inferior head of the lateral pterygoid muscles
bilaterally, in addition to 15 units into each masseter, were reported to be
helpful in reducing bruxism and tongue biting.12
Tetrabenazine may reduce dystonia including tongue protrusion for
sustained periods of time (Brandon Barton, MD, personal commu-
nication). It should be started at 12.5 mg/day, increasing weekly as
tolerated to a total of 50 mg/day in divided doses, with close
monitoring for parkinsonism and depression. Other authors have
reported worsening of dysphagia with this medication.13
Truncal and limb chorea and dystonia. Severe neck (“head drops”) and
truncal flexion/extension movements are often seen and are likely to
be choreic in nature rather than being due to motor impersistence or
dystonia. The gait can appear quite bizarre and “rubbery,” with
buckling at the knees and hips, a feature which otherwise raises
suspicion of a psychogenic gait disorder. Despite a severely abnormal
gait, balance can be remarkably preserved with relatively few falls. The
feet are often plantar-flexed and inverted due to dystonia, sometimes in
combination with a peripheral neuropathy. This lower leg dystonia
may respond to botulinum toxin injections.
Dystonia was reported to respond to levodopa in two patients
(benserazide/levodopa 25/100/three times daily [t.i.d]),14 although
this medication is not typically helpful. Typical anti-dystonia
medications, including anticholinergics (e.g., trihexiphenidyl 1 mg
per oral [p.o.] daily, increasing to 2 mg t.i.d and higher if tolerated),
benzodiazepines (e.g., clonazepam 0.25 mg daily, increasing to 0.5 mg
t.i.d and higher if tolerated), and baclofen (5 mg t.i.d, increasing as
tolerated) may be tried. Tetrabenazine can be considered, although it
is not always beneficial.13 Amantadine (200 mg/day) has been
reported to reduce chorea.15 Doses of 100 mg t.i.d. or four times
daily (q.i.d.) may also be tried.
In selected patients, DBS of the ventro-postero-lateral region of the
globus pallidus pars interna (GPi) may result in a sustained reduction
in chorea and dystonia including feeding dystonia, trunk movements,
and head banging.4,16 Positive effects were also seen for self-mutilation
and tongue biting. In two cases, additional stimulation of the thalamic
ventralis oralis region was required for adequate control of the
involuntary movements.17
Worsening of chorea during pregnancy has been noted (Pietro
Mazzoni, MD, PhD, personal communication), with improvement
following delivery.18
One case was reported of a young female with ChAc who suffered
from severe knee pain due to joint destruction as a consequence of
leg hypotonia and involuntary movements.19 She underwent joint
replacement with marked improvements in pain and functioning,
illustrating that the presence of a progressive neurodegenerative
condition should not preclude orthopedic intervention.
Parkinsonism. Parkinsonism can be a presenting sign20 or the primary
movement disorder present.21 However, bradykinesia usually develops
later,22 which may suggest a similar progression of neurodegeneration
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to that seen in Huntington’s disease (HD), with a “burnout” of the
hyperkinetic movements. Amantadine (200 mg/day) was reported to
improve gait.21 Levodopa (1,000 mg/day) may have a weak effect20,22
or be ineffective,22,23 consistent with evidence that there may be
degeneration of both pre-22 and post-synaptic neurons,24 which would
limit the effectiveness of these medications. Doses of levodopa up to
2,000 mg/day in divided doses with a peripheral dopa-decarboxylase
inhibitor may be tried as tolerated. DBS of the GPi did not improve
parkinsonism.4
Tics. Tics, both motor and vocal, can suggest a diagnosis of Tourette
syndrome prior to emergence of the full neurologic syndrome of
ChAc.25 Self-mutilation seems to be due to behavioral compulsion26
and may include severe tongue, lip, cheek, or finger biting or throwing
the body to the floor. It has been observed that a mouth guard also
reduced obsessive-compulsive behaviors and tics,27 suggesting that the
neuronal circuits controlling these behaviors may be closely linked.28
Levetiracetam (250 mg twice daily [b.i.d.])29 or benztropine,
quetiapine, and lorazepam in combination30 have been reported to
reduce tics. The effects of traditional medications for tics in ChAc have
not yet been described.
Speech and swallowing issues. Impairment of speech and swallowing
are early features of ChAc. Dysarthria due to dystonia affecting the
tongue and jaw is an invariable feature. In later stages, patients may
become completely anarthric. The use of communication devices such
as communication boards, keyboards, and computer-assisted speech
are often critical to maintain communication.
Dysphagia can be due to tongue dystonia with eating and also to
impaired coordination of the oropharyngeal musculature. Aspiration
is a major risk, as patients adopt dramatic maneuvers to swallow
food, such as extending the head and throwing food into the back of
the throat. As in HD, weight loss is common, possibly for metabolic
reasons, and nutrition should be closely monitored. It is often
necessary to consider a percutaneous endoscopic gastrostomy (PEG)
at relatively early disease stages to safely maintain adequate
nutrition. DBS of the GPi did not significantly improve speech and
swallowing.4
Psychiatric symptoms. Psychiatric symptoms can often be the initial
signs of basal ganglia dysfunction in ChAc, similar to other basal
ganglia neurodegenerative disorders. As in HD, the psychiatric
features can be more disabling than the motor symptoms, and
treatment of these symptoms may play a large role in improving
quality of life.
Obsessive-compulsive behavior is not uncommon in ChAc, as is
depression.31 These symptoms should be aggressively treated, for
example using selective serotonin re-uptake inhibitors such as
citalopram (40 mg/day).32 High doses of quetiapine (600 mg/day)
are also reported to be effective.33
Frontal disinhibition can result in apparently criminal behaviors and
can be very challenging to manage.
Seizures. Unlike most other choreiform disorders, seizures are seen in
approximately 40% of patients with ChAc (but also McLeod
syndrome).34,35 These are often an early or presenting sign and
typically originate in the temporal lobe.29,36,37 Conventional anti-
convulsant agents are usually effective, although, rarely, seizures are
refractory to multiple drugs.29 Lamotrigine may worsen tics.29 Bilateral
seizure origin was recognized using intracranial electroencephalogra-
phy in a patient who was being evaluated for epilepsy surgery.36 In
general, patients with ChAc are poor candidates for this neurosurgical
intervention.
Cardiac and other autonomic nervous system manifestations. Cardiac
involvement, specifically cardiomyopathy, has been rarely reported in
ChAc. Dilated cardiomyopathy was reported in a 40-year-old male in
whom McLeod syndrome had been excluded, although genetic
confirmation of ChAc was not performed.38 Left ventricular
hypertrophy was reported in a 34-year-old patient with genetically
confirmed ChAc who also had tobacco-related pulmonary disease.39
He died suddenly 4 years later, which was presumed by the authors to
be due to cardiac causes. Another patient in this report carried an
identical mutation but did not develop cardiac disease; thus, the
significance of these findings is unclear.
Autonomic nervous system dysfunction with orthostatic hypotension
and bradycardia has been described40,41 and is attributed to peripheral
post-ganglionic sympathetic denervation. These authors hypothesize
that denervation hypersensitivity to norepinephrine may cause fatal
arrhythmias and may account for reports of sudden death.42
Pacemaker implantation has been useful in the treatment of sustained
bradycardia (Barbara Karp, MD, personal communication).
McLeod syndrome
Chorea and dystonia. When movement disorder aspects are more
prominent, the phenotype of McLeod syndrome can be very similar to
that of ChAc. However, the presentation of McLeod syndrome may
vary considerably, and the movement disorders may be minimal. As
McLeod syndrome is an X-linked recessive disorder, it typically
presents in males; however, female carriers may develop the
condition.43,44 The onset is usually in middle age in contrast to the
young-adult onset of ChAc.
Treatment of movement disorders is symptomatic but is often not
required. When present these can include chorea, dystonia, and
parkinsonism. The latter symptom can be a presenting sign or emerge
as the disease evolves from hyper- to hypo-kinetic movements.45 Head
drops46 and orolingual dystonia with feeding, otherwise suggestive of
ChAc, are rare,47 and self-mutilating lip biting has not been reported.
Positive results have been reported with DBS of the GPi.48
Neuropathy and myopathy. The myopathy of McLeod syndrome is
due to axonal neuropathy. It is typically mild and subclinical but
occasionally may be very debilitating,49–51 contrary to what was
originally hypothesized.52 Rhabdomyolysis has occasionally been
reported.53
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Psychiatric symptoms. A variety of psychiatric or cognitive issues may
be seen, often as presenting symptoms,54 although they are not always
present. These should be treated using conventional methods.
Cardiac disease. Cardiac disease is one of the most important aspects
in McLeod syndrome, and presents a valuable opportunity for active
disease management.55,56 Annual echocardiography is recommended
for early detection of potentially treatable cardiomyopathy or
arrhythmias.56,57 Heart transplantation may be an option, as it is in
other genetic cardiomyopathic conditions.
Hematologic issues. The X-linked “McLeod phenotype” was first
identified in 1961 by the erythrocyte phenotype of reduced Kell and
absent Kx antigen cell-surface expression.58,59 The causative muta-
tions of the XK gene on the X chromosome result in absent or
dysfunctional XK protein.60 XK is linked to Kell by a disulfide bond;61
thus, when XK is absent or not present on the membrane, there is
reduced expression of the 23 antigens normally expressed by Kell.
Some patients are identified prior to the development of neurological
symptoms if they undergo blood typing.
The Kell antigen system is the third most important erythrocyte
antigen system after ABO and Rh. When individuals with the McLeod
red cell phenotype are transfused with Kell-positive blood, there is also
a risk of developing anti-Kell antibodies. If they require subsequent
transfusions, there is a risk of transfusion reactions with donor cell
hemolysis.62 Thus, it is recommended that people with McLeod
syndrome bank their own blood for autologous donation in case of
future need or for donation to others.
In addition to the presence of acanthocytosis, the membrane
abnormalities due to the absence of normal XK usually result in a
mild, compensated hemolytic anemia. However, there are no
particular issues with respect to freezing or thawing McLeod
erythrocytes, despite the apparent increase in red cell membrane
fragility (Connie Westhoff, PhD, personal communication). Subjects
may donate blood every 8 weeks, as long as their hemoglobin level is
above 12.5 g/dL.
As XK is contiguous with the gene for chronic granulomatous
disease,63 there are a number of individuals with both conditions. Due
to their medical vulnerability, these patients often need blood
transfusions.
Causes of morbidity in NA
The natural history of these disorders, similar to other neurode-
generative conditions such as PD and HD, is one of progressive motor
debility. Dysphagia tends to occur relatively earlier in ChAc than in
these other conditions, and PEG placement should not necessarily be
regarded as a pre-terminal event as it may be critical for maintaining
adequate nutrition and preventing further weight loss. Even though
patients often develop tricks for eating to overcome tongue dystonia,
these often put them at risk of pneumonia, and safety in swallowing
must be emphasized.
Loss of insight and behavioral disinhibition are difficult to manage
and may put patients at risk for falls other accidents.
Sudden, apparently unexplained death seems to occur quite
frequently in ChAc. In some cases it may be due to status epilepticus
(personal observation), while in others seizures do not constitute a
likely explanation, being either apparently absent or well-controlled.
Aspiration may be responsible in some of these cases. Alternatively, it is
possible that cardiac arrhythmia may be the cause of sudden death.
This latter possibility has not been adequately studied in these patients,
although cardiomyopathy and dysrhythmia are well-recognized in
McLeod syndrome.
Performing clinical trials in ultra-rare disorders
Carrying out double-blind, placebo-controlled trials in very rare,
slowly progressive, neurodegenerative disorders such as those discussed
is inevitably challenging. Even the collation of a retrospective series of
15 patients with ChAc who underwent DBS presented many
challenges regarding data collection and making the data acceptable
for publication.
Single-subject, randomized, double-blind, cross-over studies (n-of-1
trials) may be an option for short evaluations of symptomatic
therapies;64,65 however, these are not ideal for longer studies of
disease-modifying therapies as disease progression may not be uniform.
Specific symptoms may even become less prominent with disease
progression (e.g., chorea may progress to parkinsonism). Intercurrent
illness may result in dramatic worsening. Other barriers to trials in rare
diseases and potential solutions are discussed in detail elsewhere.66
A web-based database has been constructed for NA syndromes; this
is piggy-backed onto the European HD database (http://www.euro-
hd.net/html/na/registry) with the aim of comprehensively document-
ing all known cases. This project has been challenging for a number of
reasons. One of the major challenges has been the protean
manifestations of these disorders, and the use of a number of clinical
rating scales to attempt to address all disease features, including the
motor scales from the Unified PD and Unified HD Rating Scales; the
Burke-Fahn-Marsden Dystonia Rating Scale; a battery of cognitive,
psychiatric, and behavioral assessments, details of seizures; and
evaluations of functional capacity. The development of a single
dedicated rating scale for ChAc and McLeod syndrome may be more
appropriate; however, validation may be a challenge for such rare
disorders.
Documentation of all known patients and their clinical status is
critical in being “trial-ready” in preparation for the launch of a clinical
trial as soon as a potential therapeutic agent is identified. An example
of this is the Treat Iron-Related Childhood-Onset Neurodegeneration
(TIRCON) project for PKAN,67 which facilitated a clinical trial (still
on-going) of the iron chelator deferiprone.68 Partnership with patient
organizations plays an important role in recruitment and investment of
patients and families in such trials. Registration of clinical trials in
databases such as www.clinicaltrials.gov and the use of social media
are important modalities for contacting individuals who might be
interested in participating in studies. Coordination over a number of
sites, likely internationally, is an additional challenge.
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Support groups
Many patients with very rare diseases find that they know more
about their disorders than their treating physicians,69 especially in the
current age of the internet. The development of Internet-based support
groups (e.g., www.rareconnect.org) and a newsletter (www.
naadvocacy.org)70 have been crucial resources for patients and
caregivers, in addition to providing useful forums for researchers
seeking clinical trial subjects.
Ongoing psychological support for patients and their caregivers is
critical to avoid despair and burnout. Projects such as raising
awareness and fund raising fulfill an important role in generating
community support and provide rewarding goals.
Discussion
Experience with therapies for ChAc and McLeod syndrome is
limited by the rarity of these conditions, with few practitioners seeing
more than a single patient in their professional careers. The literature
is limited to case reports and small, retrospective, case series. As these
disorders are progressive, and manifestations may change over time,
periodic tapering of medications is recommended to determine their
benefits.
Double-blind, randomized, controlled trials are the research
standard for validating new therapies; however, different methodolo-
gies, such as n-of-1 trials, may be required for such rare conditions.
The availability of a current, comprehensive database enables us to be
trial-ready in the event of identification of a potential therapy. In the
meantime, a holistic, ongoing, and pro-active multidisciplinary
approach with achievable goals and coordination of therapeutic
interventions provides the best care for patients with these progressive
devastating diseases.
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